GI side-effect advantage for AstraZeneca and Pozen's NSAI/PPI combo but delays possible
This article was originally published in Scrip
Executive Summary
Two Phase III studies of AstraZenecaand Pozen's NSAI/PPI combination product PN 400 (enteric-coated naproxen 500mg and immediate-release esomeprazole 20mg), have confirmed its improved GI safety profile when compared with enteric-coated naproxen 500mg, however, the endpoint used may not satisfy the US FDA.